Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often
ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing
(RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive …